78056-60-7

Basic information

• Product Name: N-Acetylpiperidine-4-acetic acid
• Synonyms: (N-Acetylpiperidin-4-yl)acetic acid;1-Acetyl-4-piperidineacetic acid;N-Acetylpiperidine-4-acetic acid;4-Piperidineacetic acid, 1-acetyl-
• CAS NO: 78056-60-7
• Molecular Formula: C₉H₁₅NO₃
• Molecular Weight: 185.2203
• Mol File: 78056-60-7.mol

Chemical Properties

• Boiling Point: 389.6 °C at 760 mmHg
• Flash Point: 189.4 °C
• Appearance: /
• Density: 1.150
• CAS DataBase Reference: N-Acetylpiperidine-4-acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: N-Acetylpiperidine-4-acetic acid(78056-60-7)
• EPA Substance Registry System: N-Acetylpiperidine-4-acetic acid(78056-60-7)

Safety Data

• Hazardous Substances Data: 78056-60-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Acetylpiperidine-4-acetic acid is used as an intermediate in the synthesis of various pharmaceutical compounds for its potential anti-inflammatory and analgesic properties, making it a valuable component in the development of treatments for pain and inflammation.
Used in Agrochemical Industry:
N-Acetylpiperidine-4-acetic acid is used as a building block in the creation of agrochemical compounds, contributing to its versatile reactivity and functional groups that are essential in the formulation of effective products for agricultural applications.
Used in Organic Compound Production:
Due to its functional groups and reactivity, N-Acetylpiperidine-4-acetic acid is utilized in the production of certain organic compounds, highlighting its importance in the synthesis of a wide range of chemical entities for various industries.

InChI:InChI=1S/C9H15NO3/c1-7(11)10-4-2-8(3-5-10)6-9(12)13/h8H,2-6H2,1H3,(H,12,13)

Upstream product

• 51052-78-9 4-piperidinylacetic acid 
• 6622-91-9 2-(pyridine-4-yl)acetic acid hydrochloride 
• 71879-59-9 ethyl (1-benzylpiperidin-4-yl)acetate 
• 40110-55-2 ethyl 2-(1-benzylpiperidine-4-ylidene)acetate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 78056-59-4 ethyl 2-(1-acetyl-4-piperidyl)acetate 
• 108-24-7 acetic anhydride 
• 73415-84-6 2-(piperidin-4-yl)acetic acid hydrochloride 

Downstream Products

• 6719-96-6 1-phenyl-2-(piperidin-4-yl)ethanone 
• 78056-63-0 2-(1-acetyl-4-piperidinyl)-1-(4-fluorophenyl)ethanone 
• 145021-97-2 1-<(tert-butyloxy)carbonyl>-4-(2-(4-fluorophenyl)-2-oxoethyl)piperidine 
• 137996-01-1 4-<2-(4-fluorophenyl)-2-oxoethyl>piperidine 
• 639468-64-7 4-(2-hydroxy-2-phenylethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 639468-66-9 4-[2-(4-fluorophenyl)-2-hydroxyethyl]piperidine-1-carboxylic acid tert-butyl ester 
• 1422444-94-7 C₁₅H₁₇F₂NO₂ 

Relevant articles and documents

CARBONYL-PIPERAZINYL AND PIPERIDINIL COMPOUNDS WHICH INHIBIT FARNESYL PROTEIN TRANSFERASE

Novel carbonyl piperazinyl and piperidinyl compounds of formula (1.0) or (1.1) and pharmaceutical compositions are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel carbonyl piperazinyl or piperidinyl compound to a biological system. In particular, the method inhibits the abnormal growth cells in a mammal such as the human being. A compound of formula (1.0) and (1.1) or a pharmaceutically acceptable salt or solvate thereof, wherein Z is a group which is (i), (ii) or (iii), wherein X1 is CH or N; X2 can be the same or different and can be CH, N, or N-O; b is 0, 1, 2, 3, 4; n and nn independently represent 0, 1, 2, 3, 4 or when X2 is CH, n and nn can be 5; R20 and R21, R1, R2 and R3 are as given in the description.

Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters

In a wide search program toward new, efficient, and fast-acting antidepressant drugs, we have prepared series of new compounds having an (aryl)(aryloxy)methyl moiety linked directly or through a methylene chain to different substituted and unsubstituted cycles (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane). These compounds have been evaluated for their affinities for serotonin (5-HT) transporter (SERT) and 5-HT1A and 5-HT2A receptors. Racemic mixtures of 4-[(aryl)(aryloxy)methyl]piperidine derivatives showed much higher affinity values for SERT than fluoxetine and resulted in lack of affinity for 5-HT 1A and 5-HT2A receptors. Some of these racemic mixtures were resolved to their enantiomers and tested for binding to norepinephrine (NE) transporter (NET), dopamine (DA) transporter (DAT), and α2 receptor. Several of these enantiomers [(-)-15b, (-)-15j, (-)-15t, (+)-15u] displayed a dual binding profile with affinities for SERT and NET with K i i = 1.9 and 13.5 nM, respectively), and further pharmacological characterization is in progress for its evaluation as a antidepressant.

Carbonyl piperazinyl and piperidinyl compounds

Novel carbonyl piperazinyl and piperidinyl compounds and pharmaceutical compositions are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel carbonyl piperazinyl or piperidinyl compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

Tricyclic compounds

Novel compounds of Formula STR1 are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the formula to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: STR1 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R20)(R21)(R46), and 5.3, 5.3A and 5.3B, wherein R is --N(R25)(R48), are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases

Novel compounds of Formula STR1 are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the Formula 1.0 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases

Novel compounds of Formula (7.0a), (7.0b) or (7.0c): STR1 are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the formula (7.0a), (7.0b) or (7.0c) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

Central cholinergic agents. IV. Synthesis and acetylcholinesterase inhibitory activities of ω-[N-ethyl-N-(phenylmethyl)amino]-1-phenyl-1-alkanones and their analogues with partial conformational restriction

Inhibitors of acetylcholinesterase (AChE) bave been designed based on a working hypothesis of the enzyme's active site. These compounds were tested for their inhibitory activities on AChE and ω-[N-ethyl-N-(phenylmethyl)amino]-1-phenyl-1-alkanones (3) were found to be potent inhibitors. Various analogues of 3 were prepared to study the effect on AChE inhibition of partial restriction of conformation. Compounds with potent AChE inhibition were further evaluated in terms of central selectivity: the ratio of central action (ameliorating effect on scopolamine-induced memory impairment using a T-maze alternation task) to peripheral action.

1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives

Novel 1,3-dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives which compounds are potent serotonin-antagonists and central nervous system depressants, having utility as antiemetic, neuroleptic and anti-congestive agents.